2-Deoxy-D-glucose
| 2-Deoxy-D-glucose[1] |
|
| IUPAC name |
2-Deoxy-D-glucose |
| Other names |
2-Deoxyglucose
2-Deoxy-D-mannose
2-Deoxy-D-arabino-hexose
2-DG |
| Identifiers |
| CAS number |
154-17-6 |
| SMILES |
O[C@H](C(CO)O[C@H](O)C1)[C@H]1O |
| Properties |
| Molecular formula |
C6H12O5 |
| Molar mass |
164.16 g/mol |
| Density |
? g/cm3 |
| Melting point |
142-144 °C
|
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references |
2-Deoxy-D-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. Glucose hexokinase traps this substance in most cells (with exception of liver and kidney) so that it makes a good marker for tissue glucose use and hexokinase activity. Many cancers have elevated glucose uptake and hexokinase levels. 2-Deoxyglucose labeled with tritium or carbon-14 has been a popular ligand for laboratory research in animal models, where distribution is assessed by tissue-slicing followed by autoradiography, sometimes in tandem with either conventional or electron microscopy.
Recent work on the ketogenic diet as a treatment for epilepsy have investigated the role of glycolysis in the disease. 2-Deoxyglucose has been proposed by Garriga-Canut et al. as a mimic for the ketogenic diet, and shows great promise as a new anti-epileptic drug.[2] Garriga-Canut et al suggest that 2-DG works, in part, by decreasing the expression of Brain-derived neurotrophic factor (BDNF). Such uses are complicated by the fact that 2-deoxyglucose does have some toxicity.
In living systems, such as in medical imaging (PET scanning), fluorodeoxyglucose is used, where one of the 2-hydrogens of 2-deoxy-D-glucose is replaced with the positron-emitting isotope fluorine-18, which emits paired gamma rays, allowing distribution of the tracer to be imaged by external gamma camera(s). This is increasingly done in tandem with a CT function which is part of the same PET/CT machine, to allow better localization of small-volume tissue glucose-uptake differences.
References
- ^ Merck Index, 11th Edition, 2886.
- ^ Mireia Garriga-Canut, Barry Schoenike, Romena Qazi, Karen Bergendahl, Timothy J Daley, Rebecca M Pfender, John F Morrison, Jeffrey Ockuly, Carl Stafstrom, Thomas Sutula & Avtar Roopra, "2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP–dependent metabolic regulation of chromatin structure", Nature Neuroscience, 9, 1382 - 1387 (2006). doi:10.1038/nn1791
|
Top